Journal of the Endocrine Society最新文献

{"title":"Genotype-phenotype correlation of biallelic DUOX2 mutations in transient and permanent congenital hypothyroidism.","authors":"Sheng-Bin Liang, Chih-Ya Cheng, Yun-Ru Chen, Yann-Jang Chen, Chia-Feng Yang, Yung-Hsiu Lu, Dau-Ming Niu","doi":"10.1210/jendso/bvag081","DOIUrl":"10.1210/jendso/bvag081","url":null,"abstract":"<p><strong>Context: </strong>Congenital hypothyroidism (CH) due to DUOX2 mutations shows marked clinical heterogeneity. While some patients recover thyroid function during early childhood, others require long-term levothyroxine (LT4) therapy. The determinants of this variability remain unclear.</p><p><strong>Objective: </strong>To determine whether baseline biochemical severity, thyroid morphology, bone maturation, and biallelic DUOX2 variant severity are associated with thyroid function recovery in DUOX2-related CH.</p><p><strong>Methods: </strong>We retrospectively studied 71 patients with biallelic pathogenic DUOX2 variants, classified into 3 outcome groups: LT4 discontinued by age 4 years (<i>n</i> = 19), LT4 discontinued after age 4 years (<i>n</i> = 25), and continued LT4 with biochemical worsening requiring dose increase (<i>n</i> = 27). Baseline thyroid function tests, thyroid volume, and bone maturation were compared among groups. Bone maturation was assessed by distal femoral epiphyseal area (DFEA) and categorized as normal (DFEA ≥0.22 cm²) or delayed. Genotype-phenotype associations were examined, including variability among patients with identical biallelic genotypes.</p><p><strong>Results: </strong>Baseline thyroid function did not differ across groups (TSH <i>P</i> = .222; T3 <i>P</i> = .314; T4 <i>P</i> = .422; free T4 <i>P</i> = .505; thyroglobulin <i>P</i> = .363). Thyroid volume (<i>P</i> = .246) and bone maturation (<i>P</i> = .238) were not significantly different. The distribution of putative severe DUOX2 alleles did not differ (<i>P</i> = .862). Identical genotypes were observed across different outcome groups, indicating divergent clinical courses.</p><p><strong>Conclusion: </strong>Baseline biochemical severity, thyroid volume, bone maturation, and DUOX2 variant severity did not reliably predict recovery in DUOX2-related CH. Substantial within-genotype heterogeneity suggests contributions from compensatory H₂O₂-generating pathways and/or other modifying factors.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 6","pages":"bvag081"},"PeriodicalIF":4.4,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13191362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148016157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skeletal muscle mitochondrial bioenergetics in pregnancy: a comparison of in vivo and in vitro outcomes.","authors":"Ericka M Biagioni, Polina M Krassovskaia, Gillian Tiralla, Kelsey H Fisher-Wellman, Chien-Te Lin, Abby D Altazan, R Caitlin Hebert, Sripallavi Yendamuri, Maninder Singh, Owen T Carmichael, P Darrell Neufer, Kristen E Boyle, Leanne M Redman, Nicholas T Broskey","doi":"10.1210/jendso/bvag093","DOIUrl":"10.1210/jendso/bvag093","url":null,"abstract":"<p><strong>Purpose: </strong>Exercise-mediated adaptations to mitochondria are well established in nongravid populations; however, the extent to which these adaptations occur during pregnancy remains unclear. Therefore, the objective of this study was to compare skeletal muscle mitochondrial bioenergetics in physically active (<i>n</i> = 10) vs sedentary (<i>n</i> = 9) pregnant women.</p><p><strong>Methods: </strong>Groups were matched for age, race, and pregravid body mass index and were studied in the second (T2; weeks 21-25) and third trimester (T3; weeks 31-35). Free-living physical activity was assessed by accelerometry and aerobic fitness by peak oxygen uptake (VO₂peak) testing. In vivo mitochondrial capacity was assessed by ³¹P-magnetic resonance spectroscopy. Primary skeletal muscle myotubes were obtained via muscle biopsy between late T2 and early T3. Mitochondrial in vitro respiration was assessed by high-resolution respirometry, and mitochondrial content was measured by Western blot and enzyme activity.</p><p><strong>Results: </strong>Despite a decline in physical activity across gestation, active women maintained a higher VO₂peak at T2 (<i>P</i> < .05) and T3 (<i>P</i> < .01) compared with sedentary. There were no differences in phosphocreatine recovery time between groups or timepoints. Myotube mitochondrial respiratory capacity was similar between groups; however, compared with sedentary mothers, active mothers demonstrated increased expression of mitochondrial complexes I, II, and IV proteins (all <i>P</i> < .05). Additionally, myotube mitochondrial efficiency (adenosine triphosphate-to-oxygen consumption ratio) measures were positively correlated with maternal VO₂peak at T3 (r = 0.49, <i>P</i> < .05), suggesting a link between fitness and mitochondrial efficiency.</p><p><strong>Conclusion: </strong>These findings suggest that late pregnancy may blunt mitochondrial adaptations to aerobic exercise despite a preservation of cardiovascular fitness. Future studies are needed to determine whether increasing activity throughout gestation can enhance mitochondrial respiration.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 5","pages":"bvag093"},"PeriodicalIF":4.4,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13142800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth hormone retesting for idiopathic isolated growth hormone deficiency during and after puberty: a systematic review.","authors":"Joeri Vliegenthart, Deveney F Wols, Jan M Wit, Wichor Bramer, Edmond H H M Rings, Erica L T van den Akker, Danielle C M van der Kaay","doi":"10.1210/jendso/bvag092","DOIUrl":"10.1210/jendso/bvag092","url":null,"abstract":"<p><strong>Context: </strong>Idiopathic isolated growth hormone deficiency (IIGHD) is difficult to diagnose due to the day-to-day variation in growth hormone (GH) secretion and limitations of GH stimulation testing (GHST). Although recombinant human GH (rhGH) is typically continued until near adult height (NAH), many patients no longer show deficiency at that point. The optimal timing and method for retesting GH secretion remain unclear.</p><p><strong>Objective: </strong>To summarize the currently available GHSTs in children with IIGHD, with particular focus on diagnostic strategies in the peripubertal period, timing of retesting, and the role of sex steroid priming.</p><p><strong>Methods: </strong>A systematic literature search was conducted in 4 databases up to June 2025. Studies were included if they reported on GH retesting in children with IIGHD. Data were extracted on patient characteristics, GHST protocols, priming strategies, cutoff values, and reversal rates. Risk of bias was assessed using the ROBINS-I tool.</p><p><strong>Results: </strong>Thirty-one studies involving 2057 patients were included. Retesting occurred after 1-2 years of rhGH treatment, during mid-puberty, or at (N)AH, with mean reversal rates of 46.4%, 46.3%, and 69.6%, respectively. Priming with sex steroids was inconsistently applied, using testosterone in boys and ethinyl estradiol in girls. A GH peak cutoff of 7 μg/L was most commonly used, though values varied. Mid-pubertal retesting may reduce false-positive diagnoses and treatment burden.</p><p><strong>Conclusion: </strong>Retesting strategies for IIGHD should be individualized based on treatment response and pubertal development. Early retesting is advised for poor responders, while mid-puberty retesting suits most patients with normal development. Priming is recommended in older prepubertal children. Standardization of GHST protocols and long-term outcome studies are needed to optimize care and reduce overtreatment.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 7","pages":"bvag092"},"PeriodicalIF":4.4,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13247589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148218239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome sequencing identifies monogenic causes in adults with metabolic diseases.","authors":"Volkan Okur, Amanda Marcus, John N Falcone, Maurice A Hurd, Sarah L Stewart, Katerine Claudio, Jyothi Manohar, Fana Dealla, Sonal Kumar, Michele Yeung, Gregory Dakin, Omar Bellorin-Marin, Cheguevara Afaneh, Lisa C Hudgins, Esther Wei, Laura Gingras, Alexandra King, Judy Tung, Atteeq U Rehman, Amanda Thomas-Wilson, Saurav Guha, Avinash Abhyankar, Ashley L Wilson, Shahid Yar Khan, Sowmya Thirumalai Srinivasa, Shruti Phadke, Priya Krithivasan, Caroline Nava, Shuibing Chen, Ryan Smith, Theresa Y MacDonald, Megan J Ritter, Laura C Alonso, Olivier Elemento, Miriam S Udler, Jessica M Peña, Vaidehi Jobanputra, Marcus D Goncalves","doi":"10.1210/jendso/bvag091","DOIUrl":"10.1210/jendso/bvag091","url":null,"abstract":"<p><strong>Context: </strong>A subset of metabolic diseases is caused by rare monogenic variants. Next-generation sequencing offers a promising approach for identifying such variants, but its application in clinical diagnostics for metabolic disease is limited and the diagnostic yield is unknown.</p><p><strong>Objective: </strong>To determine the diagnostic yield of clinical genome sequencing (GS) in adults presenting with common metabolic diseases.</p><p><strong>Methods: </strong>We performed clinical GS on 560 adults seen in New York clinical practices between August 2020 and December 2023. Participants presented with hyperlipidemia/hypertriglyceridemia (HLD/HTG), pre-diabetes, Type 2 diabetes mellitus (T2DM), and/or metabolic dysfunction-associated fatty liver disease/steatohepatitis (MAFLD/MASH). Variants in a curated set of 90 genes associated with monogenic forms of these conditions were classified as Pathogenic (P), Likely Pathogenic (LP), or Variant of Uncertain Significance (VUS) using ACMG/ClinGen guidelines. P/LP variants in ACMG secondary findings (v3.1) genes were also reported with participant consent.</p><p><strong>Results: </strong>The cohort had a female-to-male ratio of 1.7, with 18.6% African American and 22.6% Latino participants. The most common enrollment diagnoses were HLD/HTG (25%), T2DM (9%), pre-diabetes (7%), and MAFLD/MASH (4%). Many participants had multiple conditions (42% with two, 12% with three). Approximately one-third had reportable variants, with 6% classified as P/LP. The most common P/LP variants were in APOB and LDLR.</p><p><strong>Conclusion: </strong>The prevalence of clinically significant (P/LP) variants related to primary metabolic disease in this cohort was 6%. An additional 5.5% of participants had P/LP variants in ACMG secondary findings genes. Future studies should refine participant selection for genome sequencing to optimize its diagnostic and clinical value.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 7","pages":"bvag091"},"PeriodicalIF":4.4,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13234609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulatory risk loci link disrupted androgen response to the pathophysiology of polycystic ovary syndrome.","authors":"Jaya Srivastava, Ivan Ovcharenko","doi":"10.1210/jendso/bvag083","DOIUrl":"10.1210/jendso/bvag083","url":null,"abstract":"<p><p>A major challenge in deciphering the complex genetic landscape of polycystic ovary syndrome (PCOS) lies in the limited understanding of how susceptibility loci drive molecular mechanisms across diverse phenotypes. To address this, we integrated molecular and epigenomic annotations from proposed causal cell types and employed a deep learning (DL) framework to predict cell type-specific regulatory effects of PCOS-risk variants. Our analysis revealed that these variants affect key transcription factor-binding sites, including <i>NR4A1/2</i>, <i>NHLH2</i>, <i>FOXA1</i>, and <i>WT1</i>, which regulate gonadotropin signaling, folliculogenesis, and steroidogenesis across brain and endocrine cell types. The DL model, which showed strong concordance with reporter assay data, identified enhancer-disrupting activity in ∼20% of risk variants. Notably, many of these variants disrupt transcription factors involved in androgen-mediated signaling, providing molecular insights into hyperandrogenemia in PCOS. Variants prioritized by the model were more pleiotropic and exerted stronger regulatory effects on gene expression compared with other risk variants. Using the <i>IRX3-FTO</i> locus as a case study, we demonstrate how regulatory disruptions in tissues such as the fetal brain, pancreas, adipocytes, and endothelial cells may link obesity-associated mechanisms to PCOS pathogenesis via neuronal development, metabolic dysfunction, and impaired folliculogenesis. Collectively, our findings highlight the utility of integrating DL models with epigenomic data to uncover disease-relevant variants, reveal cross-tissue regulatory effects, and refine mechanistic understanding of PCOS.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 5","pages":"bvag083"},"PeriodicalIF":4.4,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical therapy in mild autonomous cortisol secretion.","authors":"Alan Kelsall, Michelle Agboola, Evie Bryden, William Healey, Katherine Tolhurst, Daniel Hind, John Newell-Price","doi":"10.1210/jendso/bvag090","DOIUrl":"10.1210/jendso/bvag090","url":null,"abstract":"<p><strong>Background: </strong>Mild autonomous cortisol secretion (MACS) has an increasing prevalence with age and is associated with cardiometabolic comorbidity and increased mortality. Current guidelines recommend the majority of patients with MACS be managed conservatively, with select people referred for laparoscopic adrenalectomy. There are currently no licensed medications for MACS.</p><p><strong>Objective: </strong>We aimed to systematically review the literature to map out the current available evidence on the use of medical therapy in the treatment of MACS and to assess the research gap. Additionally, we sought to establish the outcome measurements used, to inform the design of future prospective clinical trials.</p><p><strong>Design: </strong>We searched MEDLINE and EMBASE from conception as well as clinical trial registries to detect all original studies of medical treatments in MACS. Titles and abstracts were screened and full articles reviewed.</p><p><strong>Results: </strong>A total of 5369 results were found from the search strategy. Thirteen studies met the inclusion criteria, of which 8 were conference abstracts and 5 full-text studies were included in the final analysis. This included 2 studies of metyrapone and 3 studies that used mifepristone. Common outcome measures included blood pressure, glucose measurements, weight, and side effect data.</p><p><strong>Conclusion: </strong>There is a considerable knowledge gap with regard to the medical management of MACS. Current available evidence consists of a handful of small, heterogeneous studies with a suggestion of a potential benefit in initiating mifepristone or metyrapone in this cohort. Our results highlight the urgent need for larger, prospective studies. To support this, we have provided suggestions for outcome measures.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 6","pages":"bvag090"},"PeriodicalIF":4.4,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13227007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148156830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of selected atypical non-neuroendocrine cancers with multiple endocrine neoplasia type 1.","authors":"Iina Yliaska, Joona Tapio, Timo A Kumpula, Vesa-Matti Pohjanen, Tapani Ebeling, Olavi Ukkola, Outi Kuismin, Minna Koivikko, Katri Pylkäs, Pasi I Salmela","doi":"10.1210/jendso/bvag080","DOIUrl":"10.1210/jendso/bvag080","url":null,"abstract":"<p><strong>Context: </strong>Multiple endocrine neoplasia type 1 (MEN1) is a hereditary tumor predisposing syndrome, characterized by typical neuroendocrine tumors in parathyroid, pituitary, and endocrine pancreas tissues (\"3P\"). MEN1 is also associated with non-neuroendocrine cancers, which are less studied.</p><p><strong>Objective: </strong>To assess the prevalence of certain non-neuroendocrine cancers associated with MEN1 in Finnish patients and compare the findings with a local control population.</p><p><strong>Design: </strong>Retrospective registry-based cohort study.</p><p><strong>Methods: </strong>113 MEN1 patients (51 males) treated at Oulu University Hospital between 1982 and 2023, with an average follow-up of 56 patient-years, were compared to a local control population (<i>n</i> = 1 045 520 males, average follow-up of 73 patient-years). Data were analyzed using descriptive statistics, survival curves, and Cox regression models.</p><p><strong>Results: </strong>Seven women with MEN1 (11.5%) had breast cancer (BC), 7 (6.2%) with papillary thyroid carcinoma (PTC), and 5 (4.4%) with renal cancers (RC). The mean age at BC diagnosis was 49 years compared to 60 in the general Finnish population. The hazard ratio (HR) for BC in female MEN1 patients was 3.79 (95% CI: 1.66-8.60) compared to controls. Pathogenic variants in established BC risk genes were not present in our MEN1 patients. The HR for PTC and RC were 9.37 (3.59-24.41) and 7.80 (2.74-22.25), respectively.</p><p><strong>Conclusion: </strong>This study demonstrates a significantly increased prevalence of BC, PTC, and RC in MEN1 patients compared to the Finnish general population. The findings support earlier BC screening in women with MEN1 and highlight the need for further research into non-neuroendocrine cancer risks in these patients.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 5","pages":"bvag080"},"PeriodicalIF":4.4,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Blautia</i>-PTGS1 co-occurrence in prolactinomas: potential implications for tumor microenvironment and invasiveness.","authors":"Zhen Ye, Jiayu Yang, Lijin Ji, Rui Han, Yifei Yu, Zhao Ye, Xufang Gu, Boyu Cai, Chenxing Ji, Nidan Qiao, Zhengyuan Chen, Zengyi Ma, Long Chen, Yankai Liao, Chengzhang Shi, Wenqiang He, Xiaoyun Cao, Xiang Zhou, Xuefei Shou, Yongfei Wang, Zhaoyun Zhang, Hongying Ye, Yichao Zhang, Qilin Zhang","doi":"10.1210/jendso/bvag085","DOIUrl":"10.1210/jendso/bvag085","url":null,"abstract":"<p><strong>Context: </strong>Prolactinomas are the most common functional pituitary adenomas. While altered gut microbiota has been observed in prolactinomas, whether these changes influence tumor behavior remains unclear. Our study integrated multi-omics data to investigate potential associations between gut microbiota composition and tumor characteristics in prolactinomas, as well as to explore potential molecular mechanisms and therapeutic pathway targets.</p><p><strong>Methods: </strong>Through 16S rRNA and mRNA sequencing of 10 paired patients, we identified <i>Blautia</i>-invasiveness associations and PTGS1 involvement in invasive heterogeneity of prolactinomas. We validated findings using large-cohort multi-omics datasets and evaluated PTGS1 as a therapeutic target in patient-derived organoids.</p><p><strong>Results: </strong><i>Blautia</i> abundance in the gut microbiota of patients with prolactinomas correlated with tumor invasiveness. Integrating tumor transcriptomic data, we observed a positive correlation between <i>Blautia</i> abundance and PTGS1 expression. We leveraged previously published large-cohort multi-omics datasets and confirmed that PTGS1 is markedly upregulated in prolactinomas, with higher expression in highly invasive tumors. Differential expression analysis of tumor mRNA-seq revealed that PTGS1-high tumors showed enrichment of extracellular matrix remodeling and immune-related pathways associated with tumor invasiveness. Finally, targeting PTGS1 with the selective inhibitor Tenidap in patient-derived prolactinoma organoids suppressed organoid proliferation and prolactin secretion.</p><p><strong>Conclusion: </strong>We identified a correlation between <i>Blautia</i> abundance and PTGS1 expression in prolactinomas, with PTGS1-high tumors showing enrichment of tumor microenvironment remodeling and immune-related pathways. These findings suggest a potential <i>Blautia</i>-PTGS1-tumor microenvironment association in prolactinomas that requires further mechanistic investigation to establish causality. <b>Keywords</b> Prolactinoma, Multi-omics, Blautia, Prostaglandin endoperoxide synthase 1, Tumor environment.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 6","pages":"bvag085"},"PeriodicalIF":4.4,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13338899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between thyroidea function and opioid agonist therapy: a prospective cohort study from Norway.","authors":"Anne Taraldsen Heldal, Jorn Henrik Vold, Kristin Viste, Fatemeh Chalabianloo, Gunnar Mellgren, Kjell Arne Johansson, Lars Thore Fadnes","doi":"10.1210/jendso/bvag079","DOIUrl":"10.1210/jendso/bvag079","url":null,"abstract":"<p><strong>Background: </strong>Opioid agonist therapy (OAT) is an essential treatment for opioid dependency. However, OAT may lead to endocrinopathy, which may impair the tolerability of treatment. Although the risk of disturbed regulation of the adrenal and gonadal axes has been extensively studied, less is known about how long-term opioid use and corresponding risk factors influence the thyroid axis. The objective of this study was to investigate associations between biomarkers of thyroid function and OAT medication as well as sociodemographic and clinical factors and concurrent use of illicit substances among patients receiving OAT.</p><p><strong>Methods: </strong>We used prospective data from 320 people receiving OAT in Bergen, Norway, from 2016 through 2023. All had 2 health assessments, including serum measurements of TSH. Descriptive statistics and a linear mixed model with coefficient and 95% CIs were performed to investigate the association between serum TSH (measured in mIU/L) and OAT medication as well as age, sex, substance use patterns, injecting use, housing status, and educational attainment at first assessment and over time.</p><p><strong>Results: </strong>Median serum TSH at first assessment in the study population was 1.8 mIU/L (interquartile range: 1.2). No association between OAT medications, sociodemographic, or clinical factors and serum TSH was found at first assessment and over time.</p><p><strong>Conclusion: </strong>The median serum TSH was within the recommended range among people receiving OAT. No association between OAT treatment and thyroid insufficiency was found. This indicates that screening for thyroid function beyond symptomatic assessment is probably not needed among patients receiving OAT.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 5","pages":"bvag079"},"PeriodicalIF":4.4,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13142799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical profile, treatment practices, and complications in chronic hypoparathyroidism in a Middle Eastern cohort.","authors":"Fauzia Rashid, Budoor Alemadi, Elamin Abdelgadir, Asnin Shah, Fatheya Alawadi, John P Bilezikian","doi":"10.1210/jendso/bvag077","DOIUrl":"10.1210/jendso/bvag077","url":null,"abstract":"<p><strong>Context: </strong>Hypoparathyroidism is a rare but clinically significant endocrine disorder with an unknown prevalence and complication burden in our region.</p><p><strong>Objective: </strong>This study aims to estimate the frequency of chronic hypoparathyroidism, assess its characteristics, and evaluate the current clinical practice of chronic postsurgical and idiopathic hypoparathyroidism in patients attending Dubai Hospital, UAE. It assesses biochemical profiles, physician monitoring practices, and their adherence to established guidelines.</p><p><strong>Methods: </strong>A retrospective observational study was conducted by reviewing medical records of all eligible patients.</p><p><strong>Results: </strong>A total of 65 patients with a mean age of 47.02 years were included, mostly female (76.9%) and diagnosed with postsurgical hypoparathyroidism (81.5%). Regular monitoring included calcium and vitamin D, but phosphate and creatinine were monitored less frequently. Patients were commonly prescribed high doses of calcium (median 2400 mg), with idiopathic cases requiring higher doses (mean 4200 mg). Monitoring for course and complications revealed that 55.4% of patients underwent renal imaging, 27.7% had brain imaging, 75.4% received electrocardiography (ECG) assessments, 35.4% had echocardiography, and 44.6% had documented ophthalmologic evaluations.</p><p><strong>Conclusion: </strong>This study provides the first epidemiological and demographic assessment of hypoparathyroidism in the UAE, highlighting both similarities and differences in frequency, revealing unique patient characteristics, treatment patterns, and monitoring practices. Compared to global trends, UAE patients demonstrated a higher calcium requirement and distinctive demographic patterns, including a younger mean age and a male predominance in idiopathic cases. Despite regular calcium and vitamin D monitoring, the study highlights suboptimal biochemical surveillance and complication screening, underscoring the need for improved adherence to clinical guidelines.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 6","pages":"bvag077"},"PeriodicalIF":4.4,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13184618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147982238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}